Cancer pill prolongs colon cancer survival in early clinical trial

Though the study was a Phase II clinical trial, the medicine KRX-0401 appeared to have success in a tough segment of oncology: metastatic colon cancer.

We haven't had a new drug in colon cancer since Erbitux and Vectibix in 2006. Keryx appears poised to open a Phase III clinical trial, and positive movement on their share price today means they'll probably have the dough to do it (otherwise get bought).

It's pretty rare for a phase II clinical trial to have positive survival results. Either this drug is poised to become the next blockbuster, or it's the flash in the pan of the week.

http://www.reuters.com/article/idUSSGE60O0KT20100125?type=marketsNews

http://www.keryx.com/page.cfm?hmid=20&smid=30&pg=19